Logo for Lipigon Pharmaceuticals

Lipigon Pharmaceuticals Investor Relations Material

Latest events

Logo for Lipigon Pharmaceuticals

Q2 2024

27 Aug, 2024
Logo for Lipigon Pharmaceuticals

Q1 2024

28 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Lipigon Pharmaceuticals

Access all reports
Lipigon Pharmaceuticals AB specializes in developing therapeutics for lipid-related disorders. The company focuses on creating drugs with unique mechanisms of action to treat diseases resulting from disruptions in the body's lipid metabolism. Their projects include treatments for severe hypertriglyceridemia, familial chylomicronemia syndrome, lipodystrophy, dyslipidemia, and acute respiratory distress syndrome. The company is headquartered in Umeå, Sweden, and its shares are listed on the OMX Stockholm.